(Q36174521)

12 August 2017

1 reference

title

Tigecycline: a novel glycylcycline (English)

1 reference

12 August 2017

Ethan Rubinstein

1

1 reference

12 August 2017

David Vaughan

series ordinal

2

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

65

1 reference

12 August 2017

issue

10

1 reference

12 August 2017

page(s)

1317-1336

1 reference

In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.

12 August 2017

cites work

1 reference

12 December 2020

A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter

1 reference

12 December 2020

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England

1 reference

12 December 2020

Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines

1 reference

12 December 2020

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

1 reference

12 December 2020

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

1 reference

12 December 2020

Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.

1 reference

12 December 2020

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

1 reference

12 December 2020

In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Resistance to macrolides and related antibiotics in Streptococcus pneumoniae

1 reference

12 December 2020

Recent developments in tetracycline antibiotics

1 reference

12 December 2020

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

1 reference

12 December 2020

The glycylcyclines: a comparative review with the tetracyclines

1 reference

12 December 2020

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

1 reference

12 December 2020

Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents

1 reference

12 December 2020

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

1 reference

12 December 2020

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

1 reference

12 December 2020

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

12 December 2020

Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus.

1 reference

12 December 2020

Resistance patterns among nosocomial pathogens: trends over the past few years

1 reference

12 December 2020

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

1 reference

12 December 2020

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

1 reference

12 December 2020

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

1 reference

12 December 2020

Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals

1 reference

12 December 2020

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

1 reference

12 December 2020

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

1 reference

12 December 2020

In vitro activities of tigecycline against the Bacteroides fragilis group

1 reference

12 December 2020

Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection

1 reference

12 December 2020

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

1 reference

12 December 2020

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

1 reference

12 December 2020

Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3.

1 reference

12 December 2020

Antibiotic resistance in 3113 blood isolates of Staphylococcus aureus in 40 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2000-2002).

1 reference

12 December 2020

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

1 reference

12 December 2020

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

1 reference

12 December 2020

10.2165/00003495-200565100-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1003947128

0 references

1 reference